Vascular Diseases for the Non-Specialist
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Aspirin for the Primary Prevention of Cardiovascular Events: a Summary of the Evidence
Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence Michael Hayden, MD; Michael Pignone, MD, MPH; Christopher Phillips, MD; Cynthia Mulrow, MD, MSc Epidemiolgy power to precisely estimate major harms such as gastrointestinal bleeding and hemorrhagic stroke.4,5 Cardiovascular disease (CVD), including ischemic coronary heart disease (CHD), stroke, and The results of these first 2 randomized, controlled peripheral vascular disease, is the leading cause of trials were available to the members of the U.S. morbidity and mortality in the United States.1 In Preventive Services Task Force at the time of their 1997, the age-adjusted mortality rate due to 1996 recommendation.4,5 At that time, the Task coronary heart disease, cerebrovascular disease, and Force found insufficient evidence to recommend for atherosclerotic disease was 194 per 100,000 people, or against routine aspirin prophylaxis for the equating to more than 500,000 deaths per year.1 The primary prevention of myocardial infarction in estimated direct and indirect costs of CHD and asymptomatic people.6 stroke were $145 billion for 1999.2 Two additional large primary prevention trials Although the benefit of aspirin for patients with were published in 1998, and another was reported in known CVD is well established,3 the question of January 2001.7, 8, 9 In light of the new evidence, the whether aspirin reduces the risk of CVD in people U.S. Preventive Services Task Force sought to without known CVD is controversial. Two early reassess the value of aspirin for the primary randomized trials of aspirin in healthy men, the U.S. -
Byoung Chan Kang, MD, Da Jeong Nam, MD*, Eun Kyoung Ahn, MD*, Duck Mi Yoon, MD, and Joung Goo Cho, MD*
Korean J Pain 2013 July; Vol. 26, No. 3: 299-302 pISSN 2005-9159 eISSN 2093-0569 http://dx.doi.org/10.3344/kjp.2013.26.3.299 |Case Report| Secondary Erythromelalgia - A Case Report - Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, *National Health Insurance Service Ilsan Hospital, Goyang, Korea Byoung Chan Kang, MD, Da Jeong Nam, MD*, Eun Kyoung Ahn, MD*, Duck Mi Yoon, MD, and Joung Goo Cho, MD* Erythromelalgia is a rare neurovascular pain syndrome characterized by a triad of redness, increased temperature, and burning pain primarily in the extremities. Erythromelalgia can present as a primary or secondary form, and secondary erythromelalgia associated with a myeloproliferative disease such as essential thrombocythemia often responds dramatically to aspirin therapy, as in the present case. Herein, we describe a typical case of a 48-year-old woman with secondary erythromelalgia linked to essential thrombocythemia in the unilateral hand. As this case demonstrates, detecting and visualizing the hyperthermal area through infrared thermography of an erythromelalgic patient can assist in diagnosing the patient, assessing the therapeutic results, and understanding the disease course of erythromelalgia. (Korean J Pain 2013; 26: 299-302) Key Words: aspirin, erythromelalgia, infrared thermography, neuropathic pain. Erythromelalgia is a rare clinical syndrome charac- Adults are more commonly involved than children and are terized by a triad of redness, increased temperature, and more likely to have the secondary form. Secondary eryth- burning pain primarily in the extremities. The term eryth- romelalgia is usually associated with myeloproliferative romelalgia, derived from the Greek words for redness and disorders such as essential thrombocythemia (ET) and pol- pain in the extremities, was coined in 1878 by Mitchell [1]. -
Venous Symposium: Overview
5/30/2017 1 5/30/2017 VENOUS SYMPOSIUM: OVERVIEW Robert W. Vorhies, M.D., F.A.C.S. Vascular and Endovascular Surgery Endovenous Therapy and Vein Aesthetics Ferrell-Duncan Clinic, Cox Health Systems WHY DO WE CARE? • Epidemiology • Disability • Historical experience • Opportunity 2 5/30/2017 EPIDEMIOLOGY QUESTION #1 Which state has nearly the same population as all the people in the US with venous disease? • A. New York • B. Florida • C. California • D. Missouri EPIDEMIOLOGY QUESTION #1 Which state has nearly the population as all the people in the US with venous disease? • A. New York • B. Florida • C. California • More than 11 million men and 22 million women between the ages of 40 and 80 years in the United States have varicose veins. • Prevalence of 20% (range, 21.8%-29.4%) • D. Missouri Peter Gloviczki, Anthony J. Comerota, Michael C. Dalsing, Bo G. Eklof, David L. Gillespie, Monika L. Gloviczki, Joann M. Lohr, Robert B. McLafferty, Mark H. Meissner, M. Hassan Murad, Frank T. Padberg, Peter J. Pappas, Marc A. Passman Joseph D. Raffetto, Michael A. Vasquez, and Thomas W. Wakefield. “The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum.” J Vasc Surg . 2011;53:2S-48S. 3 5/30/2017 EPIDEMIOLOGY QUESTION #2 • Which mid western metropolitan area has about the same number of people as those with severe chronic venous insufficiency including ulcers and skin changes? • A. Minneapolis • B. Chicago • C. St. Louis • D. Kansas City. EPIDEMIOLOGY QUESTION #2 • Which mid western city has about the same number of people as those with severe chronic venous insufficiency including ulcers and skin changes? • A. -
Hemorrhoids Information, Pictures, Treatments, and Cures by Rick Shacket DO, 1989 ©
Hemorrhoids Information, Pictures, Treatments, and Cures By Rick Shacket DO, 1989 © Hemorrhoids are cushions of tissue and varicose veins located in and around the rectal area. When they become inflamed, hemorrhoids can itch, bleed, and cause pain. Unfortunately a hemorrhoidal condition only tends to get worse over the years. That is why safe, gentle, and effective treatment for hemorrhoids is recommended as soon as they occur. Hemorrhoids bother about 89% of all Americans at some time in their lives. Hemorrhoids caused Napoleon to sit side-saddle, sent President Jimmy Carter to the operating room, and benched baseball star George Brett during the 1980 World Series. Over two thirds of all healthy people reporting for physical examinations have hemorrhoids. For more information about Hemorrhoids visit the links below: • Pictures: Hemorrhoids and Anal Fissure • Stapled Hemorrhoidopexy (PPH Procedure) • What Are Hemorrhoids? • Harmonic Scalpel Hemorrhoid surgery • What Are the Symptoms of Hemorrhoids? • Laser Surgery for Hemorrhoids • How Common Are Hemorrhoids? • Atomizing Hemorrhoids • How Are Hemorrhoids Diagnosed? • Complications of Hemorrhoid Surgery • What Is the Treatment? • Knowing What to Ask Your Surgeon • How Are Hemorrhoids Prevented? • Allopathic Hemorrhoid Medications • Painless Treatment of Hemorrhoids • Herbal Hemorrhoid Medications • HAL-RAR Method Hemorrhoidectomy • Homeopathic Hemorrhoid Medications • Hemorrhoids Grades 1 to 4 • References • Surgical Classification of Hemorrhoids • Video References • Traditional Surgery for Hemorrhoids Pictures: Hemorrhoids and Anal Fissure Internal hemorrhoids occur higher up in the anal canal, out of sight. Bleeding is the most common symptom of internal hemorrhoids, and often the only one in mild cases. View hemorrhoid gallery for detailed photos. Hemorrhoids Information, Pictures, Treatments, and Cures Page 1 of 21 External hemorrhoids are visible-occurring out side the anus. -
Normal Blood Supply to Equine Radii and Its Response to Various Cerclage Devices
NORMAL BLOOD SUPPLY TO EQUINE RADII AND ITS RESPONSE TO VARIOUS CERCLAGE DEVICES by KAREN ANN NYROP B.S., Montana State University, 1977 D.V.M., University of Minnesota, 1981 A MASTER'S THESIS Submitted in partial fulfillment of the requirements for the degree MASTER OF SCIENCE Department of Surgery and Medicine Kansas State University Manhattan, Kansas 1934 Approved by: H. Rodney Ferguson, jy.V.M, Ph.D. Major Professor /_£ A11EDE Tt.0443 yif TABLE OF CONTENTS Page //17 LIST OF FIGURES Hi ACKNOWLEDGEMENTS i* INTRODUCTION v LITERATURE REVIEW 1 Blood Supply of a Long Bone 1 Microangiography and Related Infusion Techniques 6 Cerclage Devices 9 2 MATERIALS AND METHODS 1 * RESULTS 18 Clinical Observations 18 Radiographic Evaluations 18 Gross Postmortem Evaluations 18 Microangiographic Evaluations 19 DISCUSSION 21 SUMMARY AND CONCLUSIONS 26 FOOTNOTES 28 BIBLIOGRAPHY 29 APPENDIX 32 ii . LIST OF FIGURES Page 1 Circumferential Partial Contact Band 32 2. Circumferential Partial Contact Band , sideview 34 3. Crossection of radius with Circumferential Partial Contact band 36 4. Anterior - posterior Radiograph of the radius of Pony 1 , Group I 38 5. Lateral - medial radiograph of the radius of Pony 1 , Group I 40 6. Microangiograph, Longitudinal section, of Control Pony 3 , Group I 42 7. Microangiograph, Crossectional view, of Control Pony 3 , Group I 44 8. Microangiograph, Crossectional view through a Cerclage Wire of Pony 1 , Group I 46 9. Microangiograph, Crossectional view through a Parham-Martin band of Pony 1 , Group I 48 10. Microangiograph, Longitudinal view with three cerclage devices in position in Pony 2, Group I 50 11. -
Venous Thromboembolism
CLINICAL PRACTICE GUIDELINES MOH/P/PAK/264.13(GU) Prevention and Treatment of Venous Thromboembolism VTE Ministry of Health Malaysian Society of National Heart Association Academy of Medicine Malaysia Haematology of Malaysia Malaysia STATEMENT OF INTENT These guidelines are meant to be a guide for clinical practice, based on the best available evidence at the time of development. Adherence to these guidelines may not necessarily ensure the best outcome in every case. Every health care provider is responsible for the management options available locally. REVIEW OF THE GUIDELINES These guidelines were issued in 2013 and will be reviewed in 2017 or sooner if new evidence becomes available. Electronic version available on the following website: http://www.haematology.org.my DISCLOSURE STATEMENT The panel members had completed disclosure forms. None held shares in pharmaceutical firms or acted as consultants to such firms (details are available upon request from the CPG Secretariat). SOURCES OF FUNDING The development of the CPG on Prevention and Treatment of Venous Thromboembolism was supported via unrestricted educational grant from Bayer Healthcare Pharmaceuticals. The funding body has not influenced the development of the guidelines. ISBN 978-967-12100-0-0 9 789671 210000 August 2013 © Ministry of Health Malaysia 01 GUIDELINES DEVELOPMENT The development group for these guidelines consists of Haematologist, Cardiologist, Neurologist, Obstetrician & Gynaecologist, Vascular Surgeon, Orthopaedic Surgeon, Anaesthesiologist, Pharmacologist and Pharmacist from the Ministry of Health Malaysia, Ministry of Higher Education Malaysia and the Private sector. Literature search was carried out at the following electronic databases: International Health Technology Assessment website, PUBMED, MEDLINE, Cochrane Database of Systemic Reviews (CDSR), Journal full teXt via OVID search engine and Science Direct. -
Proefschrift-Banne-Nemeth.Pdf
Stellingen behorende bij het proefschrift Venous thrombosis following lower-leg cast immobilization and knee arthroscopy From a population-based approach to individualized therapy 1. A prophylactic regimen of low-molecular-weight-heparin for eight days after knee arthroscopy or during the complete immobilization period in patients with casting of the lower leg is not efective for the prevention of symptomatic venous thromboembolism. -this thesis- 2. For patients with a history of venous thromboembolism who are undergoing surgery or are treated with a lower leg cast, the risk of recurrent venous thromboembolism is high. -this thesis- 3. Estimating the risk of venous thromboembolism risk following lower leg cast immobilization or following knee arthroscopy is feasible by using a risk prediction model. -this thesis- 4. A targeted approach, by identifying high-risk patients who may beneft from a higher dose or longer duration of thromboprophylactic therapy, is a promising next step to prevent symptomatic VTE following lower leg cast immobilization or knee arthroscopy. -this thesis- 5. The best treatment strategy to prevent symptomatic venous thromboembolism following lower leg cast immobilization or following knee arthroscopy is yet to be determined. 6. Prognostic models are meant to assist and not to replace clinicians’ decisions. Accurate estimation of risks of outcomes can enhance informed decision making with the patient. -Adapted from PLoS Med 10(2): e1001381- 7. The frst developed prediction model is not the last. 8. Voor de dagelijkse klinische praktijk is het essentieel dat onderzoeksresultaten op de juiste manier worden geïnterpreteerd en toegepast. Om dit te waarborgen is een intensievere samenwerking tussen epidemiologen en dokters aan te raden. -
Portal Hypertensionand Its Radiological Investigation
Postgrad Med J: first published as 10.1136/pgmj.39.451.299 on 1 May 1963. Downloaded from POSTGRAD. MED. J. (I963), 39, 299 PORTAL HYPERTENSION AND ITS RADIOLOGICAL INVESTIGATION J. H. MIDDLEMISS, M.D., F.F.R., D.M.R.D. F. G. M. Ross, M.B., B.Ch., B.A.O., F.F.R., D.M.R.D. From the Department of Radiodiagnosis, United Bristol Hospitals PORTAL hypertension is a condition in which there branch of the portal vein but may drain into the right is an blood in the branch. abnormally high pressure Small veins which are present on the serosal surface portal system of veins which eventually leads to of the liver and in the surrounding peritoneal folds splenomegaly and in chronic cases, to haematem- draining the diaphragm and stomach are known as esis and melaena. accessory portal veins. They may unite with the portal The circulation is in that it vein or enter the liver independently. portal unique The hepatic artery arises normally from the coeliac exists between two sets of capillaries, i.e. the axis but it may arise as a separate trunk from the aorta. capillaries of the spleen, pancreas, gall-bladder It runs upwards and to the right and divides into a and most of the gastro-intestinal tract on the left and right branch before entering the liver at the one hand and the sinusoids of the liver on the porta hepatis. The venous return starts as small thin-walled branches other hand. The liver parallels the lungs in that in the centre of the lobules in the liver. -
Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin
Thrombosis Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin Guest Editors: Christian Doutremepuich, Jawad fareed, Jeanine M. Walenga, Jean-Marc Orgogozo, and Marie Lordkipanidzé Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin Thrombosis Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin Guest Editors: Christian Doutremepuich, Jawad fareed, Jeanine M. Walenga, Jean-Marc Orgogozo, and Marie Lordkipanidze´ Copyright © 2012 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Thrombosis.” All articles are open access articles distributed under the Creative Commons Attribu- tion License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board Louis M. Aledort, USA Thomas Kickler, USA Johannes Oldenburg, Germany David Bergqvist, Sweden S. P. Kunapuli, USA Graham F. Pineo, Canada Francis J. Castellino, USA Jose A. Lopez, USA Domenico Prisco, Italy M. Cattaneo, Italy C. A. Ludlam, Uk Karin Przyklenk, USA Beng Hock Chong, Australia Nageswara Madamanchi, USA Ashwini Koneti Rao, USA Frank C. Church, USA Martyn Mahaut-Smith, UK F. R. Rickles, USA Giovanni de Gaetano, Italy P. M . Ma nnu cc i, Ita ly Evqueni Saenko, USA David H. Farrell, USA Osamu Matsuo, Japan Paolo Simioni, Italy Alessandro Gringeri, Italy Keith R. McCrae, USA C. Arnold -
The Approach to Thrombosis Prevention Across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
Review The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms Steffen Koschmieder Department of Medicine (Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation), Faculty of Medicine, RWTH Aachen University, Pauwelsstr. 30, D-52074 Aachen, Germany; [email protected]; Tel.: +49-241-8080981; Fax: +49-241-8082449 Abstract: Patients with myeloproliferative neoplasm (MPN) are potentially facing diminished life expectancy and decreased quality of life, due to thromboembolic and hemorrhagic complications, progression to myelofibrosis or acute leukemia with ensuing signs of hematopoietic insufficiency, and disturbing symptoms such as pruritus, night sweats, and bone pain. In patients with essential thrombocythemia (ET) or polycythemia vera (PV), current guidelines recommend both primary and secondary measures to prevent thrombosis. These include acetylsalicylic acid (ASA) for patients with intermediate- or high-risk ET and all patients with PV, unless they have contraindications for ASA use, and phlebotomy for all PV patients. A target hematocrit level below 45% is demonstrated to be associated with decreased cardiovascular events in PV. In addition, cytoreductive therapy is shown to reduce the rate of thrombotic complications in high-risk ET and high-risk PV patients. In patients with prefibrotic primary myelofibrosis (pre-PMF), similar measures are recommended as in those with ET. Patients with overt PMF may be at increased risk of bleeding and thus require a more individualized approach to thrombosis prevention. This review summarizes the thrombotic Citation: Koschmieder, S. The risk factors and primary and secondary preventive measures against thrombosis in MPN. Approach to Thrombosis Prevention across the Spectrum of Keywords: myeloproliferative neoplasms (MPN); polycythemia vera (PV); essential thrombocythemia Philadelphia-Negative Classic (ET); primary myelofibrosis (PMF); thrombosis; prevention; antiplatelet agents; anticoagulation; cy- Myeloproliferative Neoplasms. -
Reprint Of: Why Are Hemorrhoids Symptomatic? the Pathophysiology and Etiology of Hemorrhoids
Seminars in Colon and Rectal Surgery 29 (2018) 160 166 À Contents lists available at ScienceDirect Seminars in Colon and Rectal Surgery journal homepage: www.elsevier.com/locate/yscrs Reprint of: Why are hemorrhoids symptomatic? the pathophysiology and etiology of hemorrhoids WilliamD1X X C. Cirocco, MD,D2X X FACS, FASCRS* Department of Surgery, University of Missouri Kansas City, Kansas City, Missouri. À ABSTRACT Hemorrhoids are a normal component of the anorectum and contribute to the mechanism of anal closure, thus providing fine adjustment of anal continence. There are numerous myths and legends associated with the disordered and diseased state of hemorrhoids. Fortunately, information obtained from modern technolo- gies including microscopic histopathology defined first the actual substance and makeup of hemorrhoids and was later combined with anorectal physiology to provide evidence establishing the underlying pathophysiol- ogy of this universal finding of the human anorectum. The sliding anal canal theory of Gass and Adams has held up and is further supported by other anatomic studies including the work of WHF Thomson, who popu- larized the term “cushions” to describe the complex intertwining of muscle, connective tissue, veins, arteries, and arteriovenous communications which constitute hemorrhoids. A loss of muscle mass in favor of connec- tive tissue over time helps explain the role of aging as a predisposing factor for symptomatic hemorrhoids. Other factors include the modern “rich” or low-residue diet leading to constipation and straining which con- tributes to prolapsing cushions. Pathologic studies also demonstrated arteriovenous communications explain- ing why hemorrhoid bleeding is typically bright red or arterial in nature as opposed to dark or venous bleeding. -
Treatment Strategies for Patients with Lower Extremity Chronic Venous Disease (LECVD)
Evidence-based Practice Center Systematic Review Protocol Project Title: Treatment Strategies for Patients with Lower Extremity Chronic Venous Disease (LECVD) Project ID: DVTT0515 Initial publication date if applicable: March 7, 2016 Amendment Date(s) if applicable: May 6th, 2016 (Amendments Details–see Section VII) I. Background for the Systematic Review Lower extremity chronic venous disease (LECVD) is a heterogeneous term that encompasses a variety of conditions that are typically classified based on the CEAP classification, which defines LECVD based on Clinical, Etiologic, Anatomic, and Pathophysiologic parameters. This review will focus on treatment strategies for patients with LECVD, which will be defined as patients who have had signs or symptoms of LE venous disease for at least 3 months. Patients with LECVD can be asymptomatic or symptomatic, and they can exhibit a myriad of signs including varicose veins, telangiectasias, LE edema, skin changes, and/or ulceration. The etiology of chronic venous disease includes venous dilation, venous reflux, (venous) valvular incompetence, mechanical compression (e.g., May-Thurner syndrome), and post-thrombotic syndrome. Because severity of disease and treatment are influenced by anatomic segment, LECVD is also categorized by anatomy (iliofemoral vs. infrainguinal veins) and type of veins (superficial veins, perforating veins, and deep veins). Finally, the pathophysiology of LECVD is designated typically as due to the presence of venous reflux, thrombosis, and/or obstruction. LECVD is common